S&P 500   3,887.43 (+2.00%)
DOW   31,574.48 (+2.08%)
QQQ   319.50 (+1.71%)
AAPL   124.54 (+2.70%)
MSFT   236.15 (+1.62%)
FB   258.43 (+0.31%)
GOOGL   2,040.46 (+0.92%)
TSLA   702.11 (+3.94%)
AMZN   3,099.65 (+0.22%)
NVDA   543.69 (-0.89%)
BABA   239.41 (+0.69%)
CGC   34.51 (+5.37%)
GE   13.20 (+5.26%)
MU   93.15 (+1.77%)
NIO   48.90 (+6.82%)
AMD   84.57 (+0.07%)
T   28.40 (+1.83%)
F   11.93 (+1.97%)
ACB   11.11 (+5.61%)
DIS   194.71 (+3.00%)
BA   226.43 (+6.80%)
NFLX   544.98 (+1.14%)
BAC   35.70 (+2.85%)
S&P 500   3,887.43 (+2.00%)
DOW   31,574.48 (+2.08%)
QQQ   319.50 (+1.71%)
AAPL   124.54 (+2.70%)
MSFT   236.15 (+1.62%)
FB   258.43 (+0.31%)
GOOGL   2,040.46 (+0.92%)
TSLA   702.11 (+3.94%)
AMZN   3,099.65 (+0.22%)
NVDA   543.69 (-0.89%)
BABA   239.41 (+0.69%)
CGC   34.51 (+5.37%)
GE   13.20 (+5.26%)
MU   93.15 (+1.77%)
NIO   48.90 (+6.82%)
AMD   84.57 (+0.07%)
T   28.40 (+1.83%)
F   11.93 (+1.97%)
ACB   11.11 (+5.61%)
DIS   194.71 (+3.00%)
BA   226.43 (+6.80%)
NFLX   544.98 (+1.14%)
BAC   35.70 (+2.85%)
S&P 500   3,887.43 (+2.00%)
DOW   31,574.48 (+2.08%)
QQQ   319.50 (+1.71%)
AAPL   124.54 (+2.70%)
MSFT   236.15 (+1.62%)
FB   258.43 (+0.31%)
GOOGL   2,040.46 (+0.92%)
TSLA   702.11 (+3.94%)
AMZN   3,099.65 (+0.22%)
NVDA   543.69 (-0.89%)
BABA   239.41 (+0.69%)
CGC   34.51 (+5.37%)
GE   13.20 (+5.26%)
MU   93.15 (+1.77%)
NIO   48.90 (+6.82%)
AMD   84.57 (+0.07%)
T   28.40 (+1.83%)
F   11.93 (+1.97%)
ACB   11.11 (+5.61%)
DIS   194.71 (+3.00%)
BA   226.43 (+6.80%)
NFLX   544.98 (+1.14%)
BAC   35.70 (+2.85%)
S&P 500   3,887.43 (+2.00%)
DOW   31,574.48 (+2.08%)
QQQ   319.50 (+1.71%)
AAPL   124.54 (+2.70%)
MSFT   236.15 (+1.62%)
FB   258.43 (+0.31%)
GOOGL   2,040.46 (+0.92%)
TSLA   702.11 (+3.94%)
AMZN   3,099.65 (+0.22%)
NVDA   543.69 (-0.89%)
BABA   239.41 (+0.69%)
CGC   34.51 (+5.37%)
GE   13.20 (+5.26%)
MU   93.15 (+1.77%)
NIO   48.90 (+6.82%)
AMD   84.57 (+0.07%)
T   28.40 (+1.83%)
F   11.93 (+1.97%)
ACB   11.11 (+5.61%)
DIS   194.71 (+3.00%)
BA   226.43 (+6.80%)
NFLX   544.98 (+1.14%)
BAC   35.70 (+2.85%)
Log in
NASDAQ:VKTX

Viking Therapeutics Stock Forecast, Price & News

$7.00
+0.26 (+3.86 %)
(As of 03/1/2021 10:16 AM ET)
Add
Compare
Today's Range
$6.54
Now: $7.00
$7.09
50-Day Range
$6.47
MA: $7.55
$9.67
52-Week Range
$3.26
Now: $7.00
$10.09
Volume4,518 shs
Average Volume1.63 million shs
Market Capitalization$518.93 million
P/E RatioN/A
Dividend YieldN/A
Beta2.02
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis. The company's lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. It is also developing VK0612, an orally available Phase 2b-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Viking Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VKTX
CUSIPN/A
Phone858-704-4660
Employees17
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.83 per share

Profitability

Net Income$-25,780,000.00

Miscellaneous

Market Cap$518.93 million
Next Earnings Date4/29/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.58 out of 5 stars

Medical Sector

360th out of 1,962 stocks

Pharmaceutical Preparations Industry

180th out of 772 stocks

Analyst Opinion: 3.6Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
$7.00
+0.26 (+3.86 %)
(As of 03/1/2021 10:16 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VKTX News and Ratings via Email

Sign-up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Viking Therapeutics (NASDAQ:VKTX) Frequently Asked Questions

Is Viking Therapeutics a buy right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last twelve months. There are currently 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Viking Therapeutics stock.
View analyst ratings for Viking Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Viking Therapeutics?

Wall Street analysts have given Viking Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Viking Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Viking Therapeutics' next earnings date?

Viking Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for Viking Therapeutics
.

How were Viking Therapeutics' earnings last quarter?

Viking Therapeutics, Inc. (NASDAQ:VKTX) issued its quarterly earnings data on Wednesday, February, 17th. The biotechnology company reported ($0.15) EPS for the quarter, hitting analysts' consensus estimates of ($0.15).
View Viking Therapeutics' earnings history
.

How has Viking Therapeutics' stock price been impacted by COVID-19?

Viking Therapeutics' stock was trading at $5.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, VKTX shares have increased by 36.9% and is now trading at $6.94.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for VKTX?

10 brokers have issued twelve-month target prices for Viking Therapeutics' shares. Their forecasts range from $12.00 to $27.00. On average, they expect Viking Therapeutics' share price to reach $16.44 in the next twelve months. This suggests a possible upside of 137.0% from the stock's current price.
View analysts' price targets for Viking Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Viking Therapeutics' key executives?

Viking Therapeutics' management team includes the following people:
  • Dr. Brian Lian Ph.D., Pres, CEO & Director (Age 55, Pay $735k)
  • Mr. Gregory S. Zante, Chief Financial Officer (Age 50)
  • Ms. Marianne Mancini, Chief Operating Officer (Age 56)
  • Mr. Michael Morneau, VP of Fin. & Admin. (Age 56)

Who are some of Viking Therapeutics' key competitors?

What other stocks do shareholders of Viking Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), SCYNEXIS (SCYX), Amarin (AMRN), Advanced Micro Devices (AMD), Verastem (VSTM), Energy Transfer (ET) and Inovio Pharmaceuticals (INO).

When did Viking Therapeutics IPO?

(VKTX) raised $20 million in an initial public offering (IPO) on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager.

What is Viking Therapeutics' stock symbol?

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

Who are Viking Therapeutics' major shareholders?

Viking Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.29%), Park West Asset Management LLC (2.04%), Northern Trust Corp (1.85%), Fiera Capital Corp (1.52%), Baker BROS. Advisors LP (0.50%) and Nuveen Asset Management LLC (0.42%). Company insiders that own Viking Therapeutics stock include Ligand Pharmaceuticals Inc and Matthew W Foehr.
View institutional ownership trends for Viking Therapeutics
.

Which institutional investors are selling Viking Therapeutics stock?

VKTX stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, SG Americas Securities LLC, Aviva PLC, Credit Suisse AG, Squarepoint Ops LLC, Trexquant Investment LP, Baker BROS. Advisors LP, and Northern Trust Corp. Company insiders that have sold Viking Therapeutics company stock in the last year include Ligand Pharmaceuticals Inc, and Matthew W Foehr.
View insider buying and selling activity for Viking Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Viking Therapeutics stock?

VKTX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, GSA Capital Partners LLP, Wells Fargo & Company MN, Blair William & Co. IL, Virtu Financial LLC, Park West Asset Management LLC, and Raymond James Financial Services Advisors Inc..
View insider buying and selling activity for Viking Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Viking Therapeutics?

Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Viking Therapeutics' stock price today?

One share of VKTX stock can currently be purchased for approximately $6.94.

How much money does Viking Therapeutics make?

Viking Therapeutics has a market capitalization of $514.48 million. The biotechnology company earns $-25,780,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.

How many employees does Viking Therapeutics have?

Viking Therapeutics employs 17 workers across the globe.

What is Viking Therapeutics' official website?

The official website for Viking Therapeutics is www.vikingtherapeutics.com.

Where are Viking Therapeutics' headquarters?

Viking Therapeutics is headquartered at 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130.

How can I contact Viking Therapeutics?

Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-704-4660 or via email at [email protected]


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.